


=> d l1
 L1 HAS NO ANSWERS
 L1 STR



G1 O,S,CH2,NH,C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
 SAMPLE SEARCH INITIATED 13:23:21 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 4299 TO ITERATE

23.3% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 82050 TO 89910
 PROJECTED ANSWERS: 2 TO 346

L2 2 SEA SSS SAM L1

=> s l1 sss full
 FULL SEARCH INITIATED 13:23:30 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 86945 TO ITERATE

100.0% PROCESSED 86945 ITERATIONS
 SEARCH TIME: 00.00.01

77 ANSWERS

L3 77 SEA SSS FUL L1

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

FILE 'CAPLUS' ENTERED AT 13:23:39 ON 22 AUG 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2003 VOL 139 ISS 8
FILE LAST UPDATED: 20 Aug 2003 (20030820/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 0.24 nM, studies for an addnl. 6 examples are provided, ranging in values from 670 to 0.24 nM. Compd. I may be used in treatment of pathol. conditions mediated by .alpha.v.beta.3 and .alpha.v.beta.5 integrins, including such conditions as tumor growth, inflammation, rheumatoid arthritis, etc..


INVENTOR(S): Thomas
 U'Prichard, David C.; Anacletio, Beth M.; Guo, Zihong; Pan, Leonard, Kristi A.
 PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 228 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060438	A1	20020808	WO 2002-US2366	20020129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PI, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169200	A1	20021114	US 2002-58215	20020129
PRIORITY APPLN. INFO.: US 2001-264260P P 20010129				
OTHER SOURCE(S): MARPAT 137:154848				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-R5 = H, halo, alkyl, etc.; R6-R9 = H, alkyl, hydroxyalkyl, etc.; R10-R13 = H, OH, alkyl, etc.; R14 = H, or a functionality that acts as a prodrug; X = O, S, CH2, etc.; a, k, v = 0, 1; i, j, m, n = 0-4], their pharmaceutically acceptable salts, prodrugs and formulations were prepd. For example, hydrogenation of acrylic ester II, prepd. from 7-[2-[(1-(2-Methoxycarbonyl-1-(pyridin-3-yl)vinyl)-1H-indol-5-yloxy)ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-Bu ester and pyridin-3-ylpropynoic acid Me ester, followed by BOC deprotection, and ester hydrolysis provided claimed indole III. Indole III inhibited human .alpha.v.beta.3-vitronectin interaction at an IC50 of


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-88-3 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-phenyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445489-89-4 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3-(phenylmethoxy)phenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445489-90-7 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[4-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445489-92-9 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 0.24 nM, studies for an addnl. 6 examples are provided, ranging in values from 670 to 0.24 nM. Compd. I may be used in treatment of pathol. conditions mediated by .alpha.v.beta.3 and .alpha.v.beta.5 integrins, including such conditions as tumor growth, inflammation, rheumatoid arthritis, etc..

IT 445489-83-8P 445489-86-1P 445489-87-2P
 445489-88-3P 445489-89-4P 445489-90-7P
 445489-92-9P 445489-93-0P 445489-94-1P
 445489-95-2P 445489-96-3P 445489-97-4P
 445489-98-5P 445489-99-6P 445490-00-6P
 445490-01-7P 445490-02-8P 445490-03-9P
 445490-04-0P 445490-05-1P 445490-06-2P
 445490-07-3P 445490-08-4P 445490-09-5P
 445490-10-8P 445490-11-9P 445490-12-0P
 445490-13-1P 445490-14-2P 445490-15-3P
 445490-21-1P 445490-22-2P 445490-23-3P
 445490-24-4P 445490-25-5P 445490-26-6P
 445490-27-7P 445492-05-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of indoles and their use as .alpha.v.beta.3 and .alpha.v.beta.5 integrin antagonists)

RN 445489-83-8 CAPLUS
 CN 1H-Indole-1-acetic acid, .alpha.-butyl-5-[[[(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 445489-86-1 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-propyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-87-2 CAPLUS


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445489-93-0 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[2-(2-methylphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445489-94-1 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[1,1'-biphenyl]-4-yl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-95-2 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3,5-dichlorophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-96-3 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3,5-difluorophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)

8/22/2003


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445489-97-4 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(3-cyanophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-98-5 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(4-cyanophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445489-99-6 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(2-methoxyphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-05-1 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(2-chlorophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445490-06-2 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(1-naphthalenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-07-3 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(4-fluorophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-08-4 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 445490-00-6 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(3-methoxyphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-01-7 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(4-methoxyphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445490-02-8 CAPLUS
CN 3-Quinolonepropanoic acid, .beta.-[5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 445490-03-9 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-(3-chlorophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-04-0 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-2-naphthalenyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445490-09-5 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 445490-10-8 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-3-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-11-9 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-2-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-12-0 CAPLUS
CN 2-Propanoic acid, 3-(4-pyridinyl)-3-[5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445490-13-1 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-14-2 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-1,3-benzodioxol-5-yl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-15-3 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[5-(methylsulfonyl)-3-pyridinyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445490-25-5 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[5-ethoxy-3-pyridinyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 445490-26-6 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-4-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 445490-27-7 CAPLUS
 CN 2-Propenoic acid, 3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-indol-1-yl- (9CI) (CA INDEX NAME)




RN 445492-05-7 CAPLUS
 CN 2-Propenoic acid, 3-phenyl-3-[5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 445490-21-1 CAPLUS
 CN 1H-Indole-1-propanoic acid, 5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 445490-22-2 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-propyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 445490-23-3 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-phenyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 445490-24-4 CAPLUS
 CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




IT 445490-64-2P 445490-75-5P 445490-77-7P
 445490-83-5P 445490-90-4P 445490-94-8P
 445490-98-2P 445491-02-1P 445491-06-5P
 445491-13-4P 445491-17-8P 445491-20-3P
 445491-23-6P 445491-26-9P 445491-29-2P
 445491-32-7P 445491-36-1P 445491-39-4P
 445491-42-9P 445491-45-2P 445491-49-6P
 445491-52-1P 445491-57-6P 445491-61-2P
 445491-64-5P 445491-70-3P 445491-76-9P
 445491-99-6P 445492-00-2P 445492-02-4P
 445492-04-6P 445492-10-4P 445492-14-8P
 445492-15-9P 445492-22-8P 445492-24-0P
 445492-26-2P 445492-29-5P 445492-30-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of indoles and their use as .alpha.v.beta.3 and .alpha.v.beta.5 integrin antagonists)
 RN 445490-64-2 CAPLUS
 CN 1H-Indole-1-acetic acid, .alpha.-butyl-5-[[[1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445490-75-5 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-propyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 445490-77-7 CAPLUS
 CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445490-83-5 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-phenyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445490-90-4 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3-(phenylmethoxy)phenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445491-06-5 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[1,1'-biphenyl]-4-yl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445491-13-4 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3,5-difluorophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 445491-17-8 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[4-cyanophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 445491-20-3 CAPLUS

Habe


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 445490-94-8 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[4-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445490-98-2 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-02-1 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[2-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN 1H-Indole-1-propanoic acid, .beta.-[2-methoxyphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445491-23-6 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[3-methoxyphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-26-9 CAPLUS
 CN 1H-Indole-1-propanoic acid, .beta.-[4-methoxyphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-29-2 CAPLUS
 CN 3-Quinolonepropanoic acid, .beta.-[5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

8/22/2003


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 445491-32-7 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-36-1 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-39-4 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 445491-52-1 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 445491-57-6 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-3-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 445491-61-2 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-2-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-64-5 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-4-pyridinyl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-70-3 CAPLUS

Habt


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445491-42-9 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-45-2 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[4-(fluorophenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 445491-49-6 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-[3-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN 1H-Indole-1-propanoic acid, .beta.-1,3-benzodioxol-5-yl-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445491-76-9 CAPLUS
CN 1H-Indole-1-propanoic acid, .beta.-[5-(methylsulfonyl)-3-pyridinyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445491-99-6 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445492-00-2 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




8/22/2003

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 445492-02-4 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-propyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445492-04-6 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-phenyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445492-10-4 CAPLUS


CN 1H-Indole-1-propanoic acid, 5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-.beta.-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445492-14-8 CAPLUS


CN 1H-Indole-1-propanoic acid, .beta.-[5-ethoxy-3-pyridinyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445492-26-2 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-[2-methylphenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 445492-29-5 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-[3-cyanophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445492-30-8 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-[3-cyanophenyl]-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 445492-15-9 CAPLUS

CN 2-Propenoic acid, 3-(2-pyridinyl)-3-[5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-indol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 445492-22-8 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-(4-methylphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 445492-24-0 CAPLUS

CN 1H-Indole-1-propanoic acid, .beta.-(3-methylphenyl)-5-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

8/22/2003

10/058,215

Page 11

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.95

153.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.65

-0.65

STN INTERNATIONAL LOGOFF AT 13:24:04 ON 22 AUG 2003


(2)

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O, S, CH2, NH, C, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:28:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5057 TO ITERATE

19.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 96878 TO 105402
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.40

0.61

STN INTERNATIONAL LOGOFF AT 13:28:34 ON 22 AUG 2003


(3)

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,CH2,NH,C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:30:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2193 TO ITERATE

45.6% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 41052 TO 46668
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

0.61

STN INTERNATIONAL LOGOFF AT 13:30:37 ON 22 AUG 2003